Your institution may have access to this item. Find your institution then sign in to continue.
Title
FDA raps liquid biopsy firm.
Abstract
The article reports on the concerns expressed by the US Food and Drug Administration (FDA) who stepped into the laboratory-developed tests sphere by sending a letter to the pharmaceutical Pathway Genomics, for marketing the unapproved genetic test CancerIntercept Detect directly to consumers.